Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27268150 | 0.87 | TSHR (0.39) | CYP2D6TSHRKDM1AMAOBRCOR1 | |
| SCHEMBL23343449 | 0.82 | CYP2D6 (0.32) | CYP2D6TSHR | |
| SCHEMBL22946556 | 0.80 | TSHR (0.35) | CYP2D6TSHR | |
| SCHEMBL24866010 | 0.80 | GBA1 (0.36) | TSHRKDM1AMAOBRCOR1ALDH1A1 | |
| SCHEMBL24267132 | 0.80 | GBA1 (0.36) | CYP2D6TSHRKDM1AMAOBRCOR1 | |
| SCHEMBL24267397 | 0.79 | GBA1 (0.36) | TSHRKDM1AMAOBRCOR1GBA1 | |
| SCHEMBL22564921 | 0.78 | TSHR (0.44) | CYP2D6TSHRKDM1AMAOBRCOR1 | |
| SCHEMBL1753502 | 0.78 | TSHR (0.43) | CYP2D6TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL24717722 | 0.78 | TSHR (0.47) | CYP2D6TSHRCYP3A4 | |
| SCHEMBL25856124 | 0.77 | CYP2D6 (0.41) | CYP2D6TSHRKDM1AMAOBRCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | CYP2D6 4179/4885TSHR 3100/4885KDM1A 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.